A Multi-Arm, Open Label, Phase II Trial of WP1066 and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

This study is testing a new drug called WP1066 alongside radiation therapy to treat newly diagnosed glioblastoma, an aggressive type of brain tumor. Researchers hope that by blocking a protein that helps cancer cells survive, they can make radiation more effective and help patients live longer.

You may be eligible if you have been newly diagnosed with a specific type of glioblastoma that does not have the IDH mutation and has an unmethylated MGMT gene. You must also have recently undergone surgery to remove the majority of the tumor.

Participants will receive the experimental drug WP1066 combined with standard radiation therapy. During the study, you will undergo regular MRI scans and provide blood or tissue samples so doctors can closely monitor your health and how the treatment is working.

This study is currently recruiting patients at medical centers in Chicago and Warrenville, Illinois. If you are interested, your medical team can help determine if this trial is the right fit for your situation.